| Today’s Big NewsJan 6, 2025 |
|
Wednesday, January 15, 2025 | 11am ET / 8am PT Discover how next-gen Protein A resins and multi-column chromatography can help biomanufacturers optimize costs, enhance purification efficiency, and improve productivity. Learn practical strategies and explore real-world case studies showcasing advanced solutions for scalable, high-throughput processes. Register now.
|
|
| By Gabrielle Masson Overall, biopharma layoffs rose ever so slightly in 2024 compared to the year before, though the number of layoff rounds across Big Pharma companies skyrocketed by 281%. |
|
|
|
By Nick Paul Taylor I-Mab has begun the new year with a pipeline pivot, pausing work on an asset Sanofi bought into last year to focus on its play for the congested CLDN18.2 space. |
By Gabrielle Masson The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs. |
Sponsored by Astellas Pharma Inc. Discover how Astellas builds innovation partnerships with ambitious organizations that share their vision to transform the lives of patients |
|
Life sciences companies face the challenge of meeting today’s performance, innovation, and competitive requirements while preparing for the unknown. Access this report to learn how to adopt the right approaches to achieve true organizational transformation by leveraging a wide array of data sources alongside a digitization strategy. Download now.
|
|
By James Waldron More than two years after acquiring Tarus Therapeutics, Portage Biotech is relaunching Tarus’ adenosine receptor antagonists in a standalone company helmed by a familiar leader. |
By James Waldron Oculis’ peptidomimetic small molecule has been shown to help protect the eyes of patients with inflammation of the optic nerve in a phase 2 study. |
By James Waldron Xeno Biosciences may have been unable to prove that its drug delivering oxygen to the gastrointestinal tract can induce weight loss, but LPOXY Therapeutics has penned a $7.5 million biobucks deal to see whether the candidate can deliver the goods in Clostridioides difficile. |
By Darren Incorvaia British tech firm Basecamp Research is making a big push forward to further its mission of developing programmable genetic medicines. The company has hired gene therapy vet John Finn, Ph.D., to be its new chief scientific officer, working out of a new office and lab space in Cambridge, Massachusetts. |
By Conor Hale The FDA has published a set of long-awaited recommendations to the industry to help ensure pulse oximeters work correctly across all skin tones. |
By Fraiser Kansteiner Even as Novo and Lilly continue to climb, Roche looks poised to remain the top drugmaker by revenue in 2025, Evaluate analysts predict. |
By Noah Tong Mimicking prior federal and state investigations into drug manufacturers, health insurer Aetna is suing in Connecticut for rigging the generic drug market. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we bring you a special conversation from earlier this month at our New York City gala, where we celebrated this year’s Fierce 50 honorees. |
|
|---|
|
|
|
Gene therapies are growing fast, but they have one big challenge ahead: making them at a commercial scale. Access this report for an important look at the critical requirements that gene therapy manufacturers should assess when starting their custom reagent journey. Download today!
|
|
| Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
